BIO-TECHNE ANNOUNCES NEXT-GENERATION HIGH THROUGHPUT SIMPLE WESTERN SYSTEM
Bio-Techne (NASDAQ: TECH) has announced the launch of the Leo™ System, a next-generation Simple Western™ instrument.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) has announced the launch of the Leo™ System, a next-generation Simple Western™ instrument. This advanced system offers:
- Higher throughput: Process up to 100 samples in a single 3-hour run
- 4-times larger experimental size compared to current systems
- Enhanced quantitative capabilities for rigorous bioanalytical methods
- Improved data quality and speed over traditional western blotting
The Leo System enables ELISA-like protein quantitation with western blotting specificity, opening up new applications in drug development, clinical biomarkers, and vaccine research. Bio-Techne expects to begin shipping the Leo System in 2025.
Positive
- Launch of Leo™ System, offering higher throughput and efficiency
- Ability to process up to 100 samples in a single 3-hour run
- 4-times larger experimental size compared to current systems
- Enhanced quantitative capabilities for bioanalytical methods
- Potential for new applications in drug development and clinical research
Negative
- Leo System not available for shipping until 2025
Details
News Market Reaction – TECH
The recorded move for TECH in the trading session of this news was -0.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Simple Western instruments are fully automated, capillary western systems designed to resolve proteins based on molecular weight followed by immunodetection. Simple Western Systems replace traditional western blotting workflows by offering improvements in data quality and speed. The enhanced quantitation, reproducibility and throughput Leo now provides makes it possible for scientists to adopt western-based readouts in applications where westerns are not typically used due to inadequate reproducibility and lack of quantitation. Leo offers ELISA-like protein quantitation with the specificity and size resolution of western blotting, enabling new applications for western-based assays ranging from target screening & validation, targeted protein degradation, gene therapy potency assays, clinical biomarker assays, and vaccine development.
"The upcoming introduction of the Leo System reaffirms Bio-Techne's commitment to advancing protein analysis technology. The ability to perform western analysis at this scale is truly game changing and will allow the adoption of Leo as a quantitative immunoassay platform in all stages of drug development and commercialization," commented Will Geist, President of Protein Sciences.
Leo is expected to begin shipping in calendar year 2025.
Get a first look at the Leo System and explore its capabilities at bio-techne.com/leo or click here to watch an introductory video.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately
Contact:
David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-next-generation-high-throughput-simple-western-system-302210756.html
SOURCE Bio-Techne Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.